Browsing Tag
Denosumab
4 posts
FDA clears mAbxience and Amneal’s denosumab biosimilars: What it means for the bone health and oncology market
Find out how Amneal and mAbxience’s FDA-approved biosimilars to Prolia and XGEVA could reshape the bone health and cancer care markets in the U.S.
Prolia and Xgeva just got rivals: FDA clears BILDYOS and BILPREVDA biosimilars for U.S. launch
The FDA has approved Henlius and Organon’s denosumab biosimilars. Find out what this means for U.S. bone health access, pricing, and investor sentiment.
Biocon (NSE: BIOCON) gains EU nod for Denosumab biosimilars Vevzuo and Evfraxy to target bone health market
Biocon Biologics receives EU approval for Denosumab biosimilars Vevzuo and Evfraxy. Find out how this milestone could reshape its European biosimilars strategy.
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo…